Biologics
DSM Biologics and Crucell Announce PER.C6(R) License Agreement with CSL Ltd.
Published in Genetics and Environmental Business Week, January 1st, 2009
DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX), announced that CSL Limited, a global biopharmaceutical company headquartered in Melbourne, Australia, signed a license agreement allowing CSL to develop protein therapeutics for multiple undisclosed disease targets on the PER.C6(R) platform. Under the terms of the agreement, CSL is responsible for the development of protein and antibody products resulting from this alliance. Financial terms of the agreement were not disclosed.
"CSL's expertise in the area of drug development and its proven track record of marketed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
More Articles from Genetics and Environmental Business Week
- Alzheimer Disease
Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease - DNA Research
With New Understanding of 24 Human DNA Sequences - 'Personalized Medicine' Can Be Practical Worldwide, According to Researcher Bob Ainuu Afamasaga - Gene Therapy
CRSTI and Medical City Hospital Dallas Currently Recruiting for a Phase 2 Clinical Trial of MYDICAR(R) for Advanced Heart Failure - Gene Therapy
Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate - Liposomes
New liposomes research reported from Nippon Shinyaku Co., Ltd. - Ovarian Cancer
National Cancer Institute Awards Small Business Innovation Research Contract to Rules-Based Medicine, Inc. - More from this issue of Genetics and Environmental Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
